CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for TRex Bio, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

TRex Bio, Inc.
269 E. Grand Ave., Suite 300
Phone: (650) 567-5582p:650 567-5582 SOUTH SAN FRANCISCO, CA  94080  United States Ticker: TRXBTRXB
Business Summary
TRex Bio, Inc. is a biotechnology company operating within the healthcare and pharmaceutical sectors. The Company specializes in leveraging computational biology tools, focusing on human tissue, to develop therapeutics for cancer and inflammatory diseases. It uses a 'deep biology' discovery engine to map human tissue Treg behavior to disease processes, identifying novel targets for therapeutic intervention. Its goal is to build a portfolio of therapies that modulate the immune system to restore human tissue immune homeostasis.
(Source: AI Generated Content – Human Reviewed & Approved)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202612/31/2025YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer M. JohnstonErwin 65 1/1/2026 5/1/2021
Chief Financial Officer BrandonHants 50 2/1/2025 2/1/2025
Chief Operating Officer LauraBerner 52 5/1/2022
7 additional Officers and Directors records available in full report.

General Information
Number of Employees: 60 (As of 8/31/2026)
Outstanding Shares: 27,445,682 (As of 10/9/2026)
Stock Exchange: NASD
Fax Number: (302) 655-5049


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, October 27, 2026